Hikma Pharmaceuticals Plc Directorate Change (5030S)
March 12 2019 - 3:02AM
UK Regulatory
TIDMHIK
RNS Number : 5030S
Hikma Pharmaceuticals Plc
12 March 2019
Hikma Board Appoints Cynthia Schwalm as Director
London, 12 March 2019 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) (Hikma) announces the appointment of Cynthia Schwalm as
an independent non-executive director effective 1 June 2019.
"I am very pleased that Cynthia will be joining the Hikma's
Board. She brings extensive, proven experience in providing strong
leadership through transformation," said Said Darwazah, Executive
Chairman. "Her extensive commercial and leadership experience in
the pharmaceutical and biotech industries, as well as her
experience as a healthcare practitioner will bring another fresh
perspective to the Board and greatly assist in our next stage of
growth."
Most recently, Cynthia was President and CEO of the North
American divisions of the global pharmaceutical companies Ipsen and
Eisai, and also held leadership positions at Amgen and Johnson
& Johnson. Cynthia is a non-executive director of Caladrius
Biosciences Inc., Kadman Group, and G1 Therapeutics Inc., where she
chairs the Compensation Committee.
She is a member of the National Association of Corporate
Directors and an angel investment group associated with the
University of North Carolina, and for nearly a decade she served on
the Women's Leadership Advisory Board at Harvard University's
Kennedy School of Government.
Cynthia holds a BSN from the University of Delaware and EMBA
from Wharton at the University of Pennsylvania.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,500 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGGUGWWUPBGQG
(END) Dow Jones Newswires
March 12, 2019 03:02 ET (07:02 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024